Dose-escalated Adaptive Radiotherapy of Thoracic Disease for Small Cell Lung Cancer

Korábbi kezelés

• Brain metastasis that has not been symptomatically stable on dexamethasone
• Previous CNS or thoracic radiotherapy
• Previous chemotherapy
• Ineligibility for platinum doublet chemotherapy
• Prior thoracic surgery
• In LS-SCLC, patients that are not eligible for concurrent chemoradiotherapy
• In ES-SCLC, patients that are not eligible for concurrent chemoradiotherapy under the experimental arm

Más betegség

• No intrathoracic disease seen to target with radiation
• Thoracic disease is contiguous to extra-thoracic sites, beyond ipsilateral supraclavicular lymph nodes
• Mixed histology disease
• Active serious infection requiring therapy
• 4 or more sites of extrathoracic disease, even if 2 or more of these are present in the same organ system
• History of another primary malignancy other than cutaneous basal cell carcinoma unless disease-free for at least 5 years
• Lack of intrathoracic disease or intrathoracic disease spread not feasible to treat with adaptive radiotherapy

Laborértékek

• CT contrast allergy or kidney disease with irreversibly low creatinine clearance inadequate for IV contrast administration (for the purposes of high quality contrast enhanced CT chest and abdomen for follow-up imaging)

Egyéb

• Life expectancy of less than 3 months
• Pregnant or breast-feeding
• Participant in development and conduct of the research study

• Minimum 18 years of age
• Biopsy proven, newly diagnosed, untreated SCLC
• Completed standard of care staging investigations including: CT chest/abdomen/pelvis, bone scan and/or or PET-CT scan, CT head or MRI brain, or chest X-ray
• Eligible for platinum doublet chemotherapy
• Eligible for thoracic radiotherapy, which can also include ipsilateral supraclavicular lymph node disease
• Capable of providing written, informed consent prior to participation in the study. Patient's legally authorized representative (LAR) may sign on behalf of the patient.
• Able and willing to comply with protocol rules and follow-up regimen
• Performance status of ECOG 0-2
• Pulmonary function tests showing FEV-1 >1.0L and DLCO > 50% predicted
• Radiation-targetable intrathoracic disease